• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 11, 2015

View Archived Issues

Appointments and advancements

Anavex Life Sciences Corp., of New York, appointed Ulrich Elben vice president of preclinical operations. Read More

Stock movers

Read More

Other news to note

Bioinvent International AB, of Lund, Sweden, said it gained access to technology making highly efficacious immune stimulatory antibodies to combat cancer. Read More

Financings

Kite Pharma Inc., of Santa Monica, Calif., priced an underwritten public offering of about 3.6 million shares of its common stock at $69 per share. Gross proceeds are expected to be about $250.1 million. Read More

Sofinnova closes new $329M fund for early stage biotech, medtech

After leading 10 of its portfolio companies to exit in the past three years for a total enterprise value of almost €3 billion, European venture capital firm Sofinnova Partners is now armed with a new €300 million (US$328.7 million) fund to support a new stream of early stage companies. The firm blew past its initial fund target of €250 million and now has a total of €1.5 billion under management. Read More

Senate committee: Price hikes threaten to topple U.S. health care system

Implementing pathways to encourage competition and placing government regulation on generic drugs that lack competition were two suggestions offered during this week's Senate Special Committee on Aging to tackle a recent spate of off-patent drug hikes epitomized by Turing Pharmaceuticals Inc., which raised the price on a 62-year-old drug by nearly 5,500 percent and limited its access to specialty pharmacies. Read More

Small molecule clears amyloid beta deposits in mouse brains

HONG KONG – A small molecule has been shown to be capable of breaking down amyloid beta deposits in a study of the brains of mice exhibiting the symptoms of Alzheimer's disease (AD), an important finding that may lead to the development of new treatments for the different stages of AD, according to the results of a study by Korean researchers. Read More

Kallyope lands $44M series A to explore gut-brain axis

Kallyope Inc., a New York-based biotech company focused on developing a platform to influence the brain via the gut, has secured its first investment, a $44 million series A financing to explore the untapped therapeutic and nutritional potential of the bidirectional communication channel. From its lab, overlooking the Empire State Building, it expects to develop its own therapeutic programs in parallel with a platform for translating gut-brain biology into a range of new therapeutic and nutritional programs. But it is "not interested in therapeutics that are just incremental," CEO Nancy Thornberry, a veteran of Merck & Co. Inc., told BioWorld Today. Read More

Sanofi Pasteur dengue vaccine gets world-first approval in Mexico

BOGOTA, Colombia – Mexico became the first country in the world this week to approve a Sanofi Pasteur vaccine for dengue, a product that has been in development for two decades. Read More

In the clinic

Relmada Therapeutics Inc., of New York, reported top-line results from a proof-of-concept pharmacokinetic study in healthy volunteers using Butab (REL-1028), an investigational, oral formulation of buprenorphine. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe